SEK2892.1m market cap
SEK167 last close
Immunovia is a Swedish company, developing antibody microarray (IMMray) diagnostics for oncology and autoimmune diseases. Tests will be run by in-house laboratories. Its lead test is IMMray PanCan-d to detect early stage pancreatic cancer.
Investment summary
Immunovia has successfully completed the optimisation study. Service sales of IMMray PanCan-d to detect early-stage pancreatic cancer (PDAC) will now potentially be from Q3 2020, an additional six month delay, which will allow further studies using 2,400 samples. The US launch depends on US lab accreditation so could take longer than management expect. The 2,000 patient PanFAM-1 prospective clinical trial is still recruiting patients and might report primary data on early-stage PDAC detection in December 2019 (although as it is still recruiting, this might be extended). Earlier-stage opportunities are: Type II diabetes, early symptoms of PDAC, lung cancer and rheumatoid arthritis. Cash at the end of FY18 was SEK447m after a cash outflow of SEK110m.
Y/E Dec |
Revenue (SEKm) |
EBITDA (SEKm) |
PBT (SEKm) |
EPS (öre) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 13.3 | (44.3) | (45.2) | (267.0) | N/A | N/A |
| 2018A | 26.1 | (84.9) | (86.5) | (467.0) | N/A | N/A |
| 2019E | 23.1 | (85.8) | (88.8) | (453.0) | N/A | N/A |
| 2020E | 13.6 | (95.2) | (99.3) | (507.0) | N/A | N/A |
| Last updated on 18/07/2019 | ||||||
Industry outlook
Management guidance remains at 2022 sales of SEK250–300m; c 50,000 privately paid tests at c US$600 per test. By 2024, guidance is for sales of SEK800–1,000m if insurance coverage is gained, based on PanFAM-1 data; c 164,000 tests.
Last updated on 18/07/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (SEKm) | 278.4 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Mats Grahn | CEO |
| Hans Liljenborg | CFO |
You may also be interested in…
- 4SC
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- Mologen
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- Selvita
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma